[go: up one dir, main page]

BRPI0909780A2 - Composições e métodos para liberação de fármaco - Google Patents

Composições e métodos para liberação de fármaco

Info

Publication number
BRPI0909780A2
BRPI0909780A2 BRPI0909780-5A BRPI0909780A BRPI0909780A2 BR PI0909780 A2 BRPI0909780 A2 BR PI0909780A2 BR PI0909780 A BRPI0909780 A BR PI0909780A BR PI0909780 A2 BRPI0909780 A2 BR PI0909780A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
drug release
drug
release
Prior art date
Application number
BRPI0909780-5A
Other languages
English (en)
Inventor
Arnaud Beduneau
Howard Gendelman
Barrett Rabinow
Jane Werling
Original Assignee
Baxter Int
Baxter Healthcare Sa
Univ Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Univ Nebraska filed Critical Baxter Int
Publication of BRPI0909780A2 publication Critical patent/BRPI0909780A2/pt
Publication of BRPI0909780B1 publication Critical patent/BRPI0909780B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0909780-5A 2008-03-05 2009-03-05 Suspensão contendo uma partícula com superfície modificada, composição farmacêutica compreendendo a referida suspensão, método para aprimorar a absorção celular de um agente ativo, uso de partículas com superfície modificada, e método de preparação de uma partícula com superfície modificada BRPI0909780B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6815108P 2008-03-05 2008-03-05
US61/068,151 2008-03-05
US20525909P 2009-01-20 2009-01-20
US61/205,259 2009-01-20
US14891709P 2009-01-30 2009-01-30
US61/148,917 2009-01-30
PCT/US2009/036185 WO2009111638A1 (en) 2008-03-05 2009-03-05 Compositions and methods for drug delivery

Publications (2)

Publication Number Publication Date
BRPI0909780A2 true BRPI0909780A2 (pt) 2015-08-11
BRPI0909780B1 BRPI0909780B1 (pt) 2022-05-03

Family

ID=40670948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909780-5A BRPI0909780B1 (pt) 2008-03-05 2009-03-05 Suspensão contendo uma partícula com superfície modificada, composição farmacêutica compreendendo a referida suspensão, método para aprimorar a absorção celular de um agente ativo, uso de partículas com superfície modificada, e método de preparação de uma partícula com superfície modificada

Country Status (8)

Country Link
US (1) US9364443B2 (pt)
EP (1) EP2259798B1 (pt)
CN (1) CN101965195A (pt)
BR (1) BRPI0909780B1 (pt)
ES (1) ES2447465T3 (pt)
IL (1) IL207569A (pt)
RU (1) RU2496482C2 (pt)
WO (1) WO2009111638A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
NZ591045A (en) 2008-08-22 2013-01-25 Baxter Int Polymeric benzyl carbonate-derivatives
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
KR102229108B1 (ko) 2011-05-03 2021-03-18 이뮤노베이티브 테라피스, 엘티디. 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
EP3401406B1 (en) 2011-09-26 2023-11-29 PreAnalytiX GmbH Stabilisation and isolation of extracellular nucleic acids
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
CN103827303B (zh) 2011-09-26 2021-10-22 普瑞阿那利提克斯有限公司 细胞外核酸的稳定化和分离
WO2014049022A1 (en) 2012-09-25 2014-04-03 Qiagen Gmbh Stabilisation of biological samples
EP2976425B1 (en) * 2013-03-18 2019-11-06 Qiagen GmbH Stabilization and isolation of extracellular nucleic acids
JP6381628B2 (ja) 2013-03-18 2018-08-29 キアゲン ゲーエムベーハー 生物試料の安定化
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
TWI491881B (zh) * 2013-10-18 2015-07-11 國立臺灣大學 胜肽組織化學診斷法
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
CN106794256B (zh) 2014-08-19 2021-04-30 西北大学 蛋白质/寡核苷酸核-壳纳米颗粒治疗剂
US11311545B2 (en) 2014-10-09 2022-04-26 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN105748073A (zh) * 2014-12-15 2016-07-13 中国科学院大连化学物理研究所 一种小鼠清醒状态下的笼具及其应用
CN104655542B (zh) * 2015-01-05 2017-06-20 北京市医疗器械检验所 一种防护产品检测用合成血液及其配制方法
EP3310342A4 (en) * 2015-06-16 2019-03-06 The Trustees of the University of Pennsylvania INORGANIC RETARD PARTICLES WITH FAST ACTIVE LOAD
WO2017085321A1 (en) 2015-11-20 2017-05-26 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
WO2017124078A1 (en) * 2016-01-16 2017-07-20 Autotelic Llc Celcoxib binding antibodies and uses thereof
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018098376A1 (en) 2016-11-22 2018-05-31 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
CN107638940A (zh) * 2017-07-31 2018-01-30 芜湖杨燕制药有限公司 一种中药注射剂渗漉提取前处理方法
RU2663588C1 (ru) * 2017-08-07 2018-08-07 Александр Александрович Кролевец Способ получения нанокапсул биопага-Д в геллановой камеди
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
RU2691954C1 (ru) * 2018-05-21 2019-06-19 Александр Александрович Кролевец Способ получения нанокапсул биопага-Д в каппа-каррагинане
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
JP2022523510A (ja) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド 粒子形成及び形態構造
RU2725764C1 (ru) * 2019-07-25 2020-07-06 Частное образовательное учреждение высшего образования "Региональный открытый социальный институт" ЧОУ ВО "РОСИ" Способ получения нанокапсул сульфата железа(III) в гуаровой камеди
RU2724890C1 (ru) * 2019-08-20 2020-06-26 Частное образовательное учреждение высшего образования "Региональный открытый социальный институт" ЧОУ ВО "РОСИ" Способ получения нанокапсул сульфата железа (III)
AU2020344675A1 (en) 2019-09-13 2022-03-31 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
RU2724887C1 (ru) * 2019-10-28 2020-06-26 Частное образовательное учреждение высшего образования "Региональный открытый социальный институт" ЧОУ ВО "РОСИ" Способ получения нанокапсул сульфата железа (III)
CN113376386B (zh) * 2020-03-09 2025-09-02 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
CN114366724B (zh) * 2021-12-29 2023-02-24 中山大学附属第一医院 一种微环境巨噬细胞调控递送系统及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
DE2656317C2 (de) 1976-12-11 1986-06-19 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur Herstellung einer Suspension von beladenen Erythrocyten
DE2656746C2 (de) 1976-12-15 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verwendung von beladenen Erythrozyten
JPS60150826A (ja) 1984-01-18 1985-08-08 Lion Corp 表面電荷をもつベシクル分散液
US4670185A (en) * 1982-07-19 1987-06-02 Lion Corporation Aqueous vesicle dispersion having surface charge
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5213788A (en) 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
FR2651680B1 (fr) 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
EP0566590B1 (en) 1991-01-07 1997-03-19 Syngenix Limited Particulates
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2144059A1 (en) 1992-09-28 1994-04-14 Patrick Aebischer Chitosan matrices for encapsulated cells
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US20050054033A9 (en) 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
EP0855906B1 (en) 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
EP0920339A2 (en) 1996-07-09 1999-06-09 The Johns Hopkins University Gene delivery system
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO1998047492A1 (en) 1997-04-18 1998-10-29 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
KR100789008B1 (ko) 1997-06-27 2007-12-26 아브락시스 바이오사이언스 인크. 신규 약물 제제
US20020068048A1 (en) 1997-09-05 2002-06-06 Patrick A. Dreyfus Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
WO2000064954A1 (en) 1999-04-22 2000-11-02 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
HK1046506B (en) 1999-09-09 2006-08-25 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
GB0002856D0 (en) 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
AU2001247244B2 (en) 2000-02-28 2005-06-02 Genesegues, Inc. Nanocapsule encapsulation system and method
JP4085231B2 (ja) 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法
US7338657B2 (en) 2001-03-15 2008-03-04 Biosphere Medical, Inc. Injectable microspheres for tissue construction
PL366025A1 (en) 2000-05-03 2005-01-24 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
CN100512798C (zh) 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002060416A1 (en) 2001-02-01 2002-08-08 Gendel Limited Polypeptide delivery system and method for their preparation
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6790455B2 (en) 2001-09-14 2004-09-14 The Research Foundation At State University Of New York Cell delivery system comprising a fibrous matrix and cells
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1186445C (zh) * 2002-03-15 2005-01-26 陈志南 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US20050058603A1 (en) * 2003-05-02 2005-03-17 Case Western Reserve University Drug delivery system based on polymer nanoshells
CN1791386A (zh) * 2003-05-19 2006-06-21 巴克斯特国际公司 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂
WO2004110270A1 (en) 2003-06-12 2004-12-23 Regents Of The University Of Minnesota Directing cells to target tissues or organs
EP1567188B1 (en) 2003-06-20 2012-07-11 Eli Lilly And Company Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
CA2540695A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US20050084456A1 (en) * 2003-10-21 2005-04-21 Liping Tang Functionalized particles
GB2407500A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Use of microparticles for antigen delivery
GB0329310D0 (en) 2003-12-18 2004-01-21 Univ Keele Method
RU2006130958A (ru) 2004-01-29 2008-03-10 Бакстер Интернэшнл Инк. (Us) Наносуспензии антиретровирусных агентов для улучшенной доставки в центральную нервную систему
PL1718338T3 (pl) 2004-02-02 2015-12-31 Engeneic Molecular Delivery Pty Ltd Kompozycje oraz sposoby do celowanego dostarczania leku in vitro oraz in vivo do ssaczych komórek poprzez bakteriopochodne nienaruszone minikomórki
AU2005255039A1 (en) 2004-06-15 2005-12-29 Baxter Healthcare S.A. Ex-vivo application of solid microparticulate therapeutic agents
US7541028B2 (en) * 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for monoclonal antibody delivery
AU2006209654A1 (en) 2005-01-28 2006-08-03 Konica Minolta Medical & Graphic, Inc. Pharmaceutical preparation containing magnetic vesicular particles, manufacturing method thereof and diagnostic therapeutic system
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
CN1772303A (zh) 2005-10-25 2006-05-17 朱宏 恶性肿瘤磁热疗用纳米磁粉－抗体靶向药物
US20070098640A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography

Also Published As

Publication number Publication date
ES2447465T3 (es) 2014-03-12
US20090274765A1 (en) 2009-11-05
BRPI0909780B1 (pt) 2022-05-03
RU2496482C2 (ru) 2013-10-27
WO2009111638A1 (en) 2009-09-11
EP2259798A1 (en) 2010-12-15
IL207569A0 (en) 2010-12-30
US9364443B2 (en) 2016-06-14
RU2010140621A (ru) 2012-04-10
IL207569A (en) 2015-11-30
CN101965195A (zh) 2011-02-02
EP2259798B1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0915460A2 (pt) métodos e composições para a liberação intensificada de macromoléculas
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012014962A2 (pt) métodos e composições para formulações líquidas e estáveis de fármacos
BRPI1011412A2 (pt) composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
EP2236149A4 (en) MEDICAL COMPOSITION
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.